Yoshimura S, Masuzaki H, Miura K, Gotoh H, Moriyama S, Fujishita A, Ishimaru T
Department of Obstetrics and Gynecology, Nagasaki University School of Medicine, Japan.
Early Hum Dev. 2000 Jan;57(1):61-9. doi: 10.1016/s0378-3782(99)00052-3.
The purpose of this study was (1) to compare the expression of epithelial growth factor receptor (EGFR) in the lung tissues of human fetuses with or without pulmonary hypoplasia, and (2) to investigate the effects of EGF on lung growth in experimental pulmonary hypoplasia in rabbits. Firstly, we investigated the expression of EGFR in lung tissues of human fetuses with or without pulmonary hypoplasia by immunohistochemistry. Secondly, the amniotic fluid was shunted into the maternal abdominal cavity in a group of 12 fetal rabbits, another group (n = 12) received EGF injection (5 microg, i.p.) at day 25 of gestation. The third group (n = 12) was only treated with EGF while littermates not operated on served as the control group (n = 12). On day 29 of gestation, fetuses were delivered by Cesarean section and the lungs removed. The body weight and wet lung and liver weights were measured. As a measure of fetal lung growth, we determined the size of lung acini, the number of terminal airspaces, and diameter of alveoli (n = 6, each groups). We also measured the concentration of phosphatidylcholine (PC) and the lecithin/sphingomyelin (L/S) ratio in lung lavage fluid at birth in some fetuses (n = 6, each groups). In human fetuses with pulmonary hypoplasia, there was a significant decrease in radial alveolar count and expression of EGFR compared with fetuses without pulmonary hypoplasia. Amniotic shunt significantly decreased fetal lung/body weight ratio compared with control. Injection of EGF in the shunted group significantly increased lung/body weight ratio to the control level. The concentration of PC and L/S ratio in lung fluid lavage from rabbit fetuses with hypoplastic lungs was significantly higher than the other three groups. Histopathological examination of fetuses with hypoplastic lungs treated with EGF showed no significant change in the size of acini, number of terminal airspaces or the diameter of alveoli compared with the control group. Our results suggested that EGF was associated with lung growth and maturation of human lung and that treatment of rabbit fetuses with hypoplastic lungs with EGF facilitated lung growth and development.
(1)比较有或无肺发育不全的人胎儿肺组织中表皮生长因子受体(EGFR)的表达;(2)研究表皮生长因子(EGF)对兔实验性肺发育不全中肺生长的影响。首先,我们通过免疫组织化学研究有或无肺发育不全的人胎儿肺组织中EGFR的表达。其次,将羊水分流至12只胎兔的母羊腹腔内,另一组(n = 12)在妊娠第25天接受EGF注射(5微克,腹腔注射)。第三组(n = 12)仅用EGF治疗,未手术的同窝仔兔作为对照组(n = 12)。在妊娠第29天,通过剖宫产取出胎儿并取出肺。测量体重、肺湿重和肝湿重。作为胎儿肺生长的指标,我们测定了肺腺泡大小、终末气腔数量和肺泡直径(每组n = 6)。我们还在一些出生时的胎儿(每组n = 6)中测量了肺灌洗液中磷脂酰胆碱(PC)的浓度和卵磷脂/鞘磷脂(L/S)比值。在有肺发育不全的人胎儿中,与无肺发育不全的胎儿相比,肺泡径向计数和EGFR表达显著降低。与对照组相比,羊水分流显著降低了胎儿肺/体重比。在分流组中注射EGF可使肺/体重比显著增加至对照组水平。肺发育不全的兔胎儿肺灌洗液中PC浓度和L/S比值显著高于其他三组。用EGF治疗肺发育不全胎儿的组织病理学检查显示,与对照组相比,腺泡大小、终末气腔数量或肺泡直径无显著变化。我们的结果表明,EGF与人肺的生长和成熟有关,用EGF治疗肺发育不全的兔胎儿可促进肺的生长和发育。